for adults with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
Approval was based on the KarMMa-3 trial, in which 254 patients were randomly assigned to ide-cel and 132 to investigators' choice of standard regimens, consisting of combinations of
FDA Ide-Cel Multiple Myeloma CAR T-Cell Therapy Relapsed Refractory Therapy
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Prinz von Anhalt Doesn't Want Son After 'Adults Adopting Adults' CanceledPrince Frederic Prinz Von Anhalt says he doesn't want his adopted son anymore, after his show 'Adults Adopting Adults' has been canceled.
Source: TMZ - 🏆 379. / 59 Read more »
FDA OKs Danicopan Add-On for Extravascular Hemolysis in Adults With PNHA tablet has been approved for a common complication during treatment for a rare blood disorder.
Source: Medscape - 🏆 386. / 55 Read more »
HBG school board approves plan for community adults to help curb student violenceThe Harrisburg School District has approved a proposal that will place vetted community adults in schools to reduce student behavioral incidents.A school board
Source: CBS21NEWS - 🏆 304. / 63 Read more »
FDA Approves First Drug for Common, Serious Liver DiseaseMillions of Americans whose livers develop scar tissue due to a common disease now have the first approved drug, Rezdiffra, to treat the condition, the U.S. Food and Drug Administration announced Thursday.
Source: MedicineNet - 🏆 575. / 51 Read more »
FDA approves first drug to treat yeast ear infections in dogsThe U.S. Food and Drug Administration has approved the first drug to treat yeast ear infections in dogs.
Source: physorg_com - 🏆 388. / 55 Read more »
FDA Approves Ponatinib for Upfront Ph+ ALLThis is the first targeted treatment approved for upfront use in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Source: Medscape - 🏆 386. / 55 Read more »